2024-04-30 16:05 | UU:MYGN | | News Release200 | Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 |
2024-04-17 08:00 | UU:MYGN | | News Release200 | Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor |
2024-04-16 09:15 | UU:MYGN | | News Release200 | New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel(TM) Prenatal Screen |
2024-04-09 08:00 | UU:MYGN | | News Release200 | Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing |
2024-03-21 21:40 | UU:MYGN | | News Release200 | Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date |
2024-03-20 16:05 | UU:MYGN | | News Release200 | Myriad Genetics Announces Patent Granted for SneakPeek(TM) Snap Device |
2024-02-27 16:05 | UU:MYGN | | News Release200 | Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the F |
2024-02-27 09:15 | UU:MYGN | | News Release200 | Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 |
2024-02-21 16:05 | UU:MYGN | | News Release200 | Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 |
2024-02-15 16:05 | UU:MYGN | | News Release200 | Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women ¢ € ™s Health |
2024-02-01 09:25 | UU:MYGN | | News Release200 | Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics |
2024-01-30 17:00 | UU:MYGN | | News Release200 | Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology |
2024-01-18 18:10 | UU:MYGN | | News Release200 | Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics |
2024-01-09 16:05 | UU:MYGN | | News Release200 | Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO |
2024-01-03 16:05 | UU:MYGN | | News Release200 | Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference |
2023-12-21 08:30 | UU:MYGN | | News Release200 | Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance |
2023-12-20 08:00 | UU:MYGN | | News Release200 | Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care |
2023-12-07 17:49 | UU:MYGN | | News Release200 | Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement |
2023-12-05 12:02 | UU:MYGN | | News Release200 | Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement |
2023-11-20 16:05 | UU:MYGN | | News Release200 | Myriad Genetics Celebrates One Million SneakPeek ‚ ® Results Shared with Expectant Parents |
2023-11-16 16:05 | UU:MYGN | | News Release200 | Myriad Genetics and Personalis Partner to Market Solutions ‚ to Pharma Customers |
2023-11-09 07:00 | UU:MYGN | | News Release200 | Myriad Genetics to Participate in Stephens Annual Investment Conference |
2023-11-08 21:20 | UU:MYGN | | News Release200 | Myriad Genetics Announces Pricing of Upsized Offering of Common Stock |
2023-11-08 16:11 | UU:MYGN | | News Release200 | Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock |
2023-11-06 16:05 | UU:MYGN | | News Release200 | Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance |
2023-11-01 09:00 | UU:MYGN | | News Release200 | Myriad Genetics Appoints Sam Raha as Chief Operating Officer |
2023-10-31 16:05 | UU:MYGN | | News Release200 | Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023 |
2023-10-26 08:00 | UU:MYGN | | News Release200 | QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer |
2023-10-26 08:00 | UU:MYGN | | News Release200 | QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer |
2023-09-28 16:59 | UU:MYGN | | News Release200 | BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD |
2023-09-28 07:00 | UU:MYGN | | News Release200 | New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood |
2023-09-19 09:00 | UU:MYGN | | News Release200 | Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials |
2023-09-19 07:00 | UU:MYGN | | News Release200 | Myriad Genetics Issues 2022 Environmental, Social and Governance Report |
2023-09-18 08:00 | UU:MYGN | | News Release200 | Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer |
2023-09-06 16:05 | UU:MYGN | | News Release200 | Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work |
2023-09-06 07:00 | UU:MYGN | | News Release200 | New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women |
2023-09-05 08:00 | UU:MYGN | | News Release200 | Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference |
2023-08-22 09:00 | UU:MYGN | | News Release200 | Myriad Genetics and Onsite Women ¢ € ™s Health Partner to Help More Women Understand Breast Cancer Risk |
2023-08-17 16:05 | UU:MYGN | | News Release200 | Myriad Genetics to Host Investor Day on September 19, 2023 |
2023-08-15 07:05 | UU:MYGN | | News Release200 | Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris ‚ ® |
2023-08-08 16:05 | UU:MYGN | | News Release200 | Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment |
2023-08-07 16:05 | UU:MYGN | | News Release200 | Myriad Genetics Announces Enhancements to the GeneSight ‚ ® Test ‚ to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status |
2023-08-03 16:05 | UU:MYGN | | News Release200 | Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth |
2023-07-27 16:05 | UU:MYGN | | News Release200 | Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023 |
2023-07-24 08:00 | UU:MYGN | | News Release200 | Myriad Genetics Announces Inclusion of Breast Density to MyRisk ‚ ® ‚ with RiskScore ‚ ® ‚ Breast Cancer Risk Assessment |
2023-07-06 08:30 | UU:MYGN | | News Release200 | Myriad Genetics Announces New $90 Million Asset-Based Credit Facility |
2023-06-12 08:00 | UU:MYGN | | News Release200 | Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform |
2023-06-07 16:05 | UU:MYGN | | News Release200 | Myriad Genetics to Participate in Goldman Sachs Healthcare Conference |
2023-06-01 08:00 | UU:MYGN | | News Release200 | Myriad Genetics Highlights Latest Oncology Portfolio Advancements ‚ and New Data at ASCO 2023 |
2023-05-31 08:00 | UU:MYGN | | News Release200 | Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics |
2023-05-24 16:05 | UU:MYGN | | News Release200 | Myriad Genetics Adds Folate Receptor Alpha to Precise ¢ „ ¢ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer |
2023-05-08 16:05 | UU:MYGN | | News Release200 | Myriad Genetics Earns 2023 Great Place to Work Certification ¢ „ ¢ |
2023-05-03 16:05 | UU:MYGN | | News Release200 | Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range |